Q2 EPS Estimates for NTLA Cut by Brookline Capital Markets

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at Brookline Capital Markets reduced their Q2 2026 earnings estimates for Intellia Therapeutics in a research report issued on Thursday, August 6th. Brookline Capital Markets analyst L. Cann now expects that the company will earn ($0.80) per share for the quarter, down from their previous estimate of ($0.75). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($3.18) per share. Brookline Capital Markets also issued estimates for Intellia Therapeutics’ Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($2.84) EPS, FY2027 earnings at $0.97 EPS, FY2028 earnings at $5.53 EPS, FY2029 earnings at $14.89 EPS and FY2030 earnings at $25.07 EPS.

Several other research firms have also recently commented on NTLA. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 15th. Leerink Partners set a $35.00 price objective on Intellia Therapeutics in a report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Friday, July 17th. The Goldman Sachs Group upped their target price on Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research report on Tuesday, April 28th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $49.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.85.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $12.02 on Monday. The business has a 50-day moving average of $13.61 and a 200-day moving average of $13.48. The company has a market capitalization of $1.68 billion, a PE ratio of -3.58 and a beta of 1.81. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.80). The company had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. Intellia Therapeutics’s revenue for the quarter was down 46.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.98) earnings per share.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Comerica Bank grew its holdings in shares of Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Intellia Therapeutics in the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new position in Intellia Therapeutics during the 3rd quarter valued at approximately $30,000. Advisory Services Network LLC acquired a new position in Intellia Therapeutics during the 3rd quarter valued at approximately $33,000. Finally, Fifth Third Bancorp bought a new position in Intellia Therapeutics during the 1st quarter worth $38,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,641 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the transaction, the chief accounting officer directly owned 66,886 shares in the company, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the sale, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. The trade was a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.50% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.